Zhuo Zushun, Nie Jianhua, Xie Bin, Wang Fei, Shi Min, Jiang Yini, Zhu Weifeng
Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, Jiangxi Province, China.
J Ethnopharmacol. 2024 Mar 25;322:117614. doi: 10.1016/j.jep.2023.117614. Epub 2023 Dec 17.
Ephedra sinica Stapf (Mahuang) and Schisandra chinensis (Turcz.) Baill (Wuweizi) are commonly utilized in traditional Chinese medicine for the treatment of cough and asthma. The synergistic effect of Mahuang-Wuweizi herb pair enhances their efficacy in alleviating respiratory symptoms, making them extensively employed in the management of respiratory disorders. Although previous studies have demonstrated the therapeutic potential of Mahuang-Wuweizi in pulmonary fibrosis, the precise mechanism underlying their effectiveness against asthma remains elusive.
The objective of this study is to investigate the mechanism underlying the preventive and therapeutic effects of Mahuang-Wuweizi herb pair on asthma progression, focusing on airway inflammation and airway remodeling.
The active constituents and potential mechanisms of Mahuang-Wuweizi in the management of asthma were elucidated through network pharmacology analysis. Liquid chromatography tandem mass spectrometry (LC-MS/MS) was used to detect the main components of Mahuang-Wuweizi decoction. A rat model of bronchial asthma was established, and the effects of Mahuang-Wuweizi were investigated using hematoxylin-eosin (HE) staining, immunohistochemistry (IHC) staining, enzyme-linked immunosorbent assay (ELISA), Western blotting (WB), and real-time reverse transcription polymerase chain reaction (RT-qPCR).
The results of network pharmacological prediction showed that Mahuang had 22 active components and Wuweizi had 8 active components, with 225 potential targets. 1159 targets associated with asthma and 115 targets that overlap between drugs and diseases were identified. These include interleukin-6 (IL-6), tumor necrosis factor (TNF), Tumor Protein 53, interleukin-1β (IL-1β), as well as other essential targets. Additionally, there is a potential correlation between asthma and Phosphatidylinositol 3 kinase (PI3K)/Protein Kinase B (AKT) signaling pathway, calcium ion channels, nuclear factor-kappa B (NF-κB) signaling pathway, and other signaling pathways. The animal experiment results demonstrated that treatment with Mahuang and Wuweizi, in comparison to the model group, exhibited improvements in lung tissue pathological injury, reduction in collagen fiber accumulation around the airway and proliferation of airway smooth muscle, decrease in concentration levels of IL-6, TNF-α and IL-1β in lung tissue, as well as alleviation of airway inflammation. Furthermore, Mahuang and Wuweizi suppressed the expression of phospholipase C (PLC), transient receptor potential channel 1 (TRPC1), myosin light chain kinase (MLCK), NF-κB P protein in ovalbumin (OVA)-sensitized rat lung tissue and downregulated the mRNA expression of PLC, TRPC1, PI3K, AKT, NF-κB P in asthmatic rats. These findings were consistent with network pharmacological analysis.
The results show that the synergistic interaction between Mahuang and Wuweizi occur, and they can effectively reduce airway remodeling and airway inflammation induced by inhaling OVA in bronchial asthma rats by inhibiting the expression of PLC/TRPC1/PI3K/AKT/NF-κB signaling pathway. Therefore, Mahuang and Wuweizi may be potential drugs to treat asthma.
麻黄(Ephedra sinica Stapf)和五味子(Schisandra chinensis (Turcz.) Baill)常用于传统中药治疗咳嗽和哮喘。麻黄 - 五味子药对的协同作用增强了它们缓解呼吸道症状的功效,使其广泛应用于呼吸系统疾病的管理。尽管先前的研究已经证明了麻黄 - 五味子在肺纤维化方面的治疗潜力,但其抗哮喘的确切机制仍不清楚。
本研究的目的是探讨麻黄 - 五味子药对预防和治疗哮喘进展的机制,重点关注气道炎症和气道重塑。
通过网络药理学分析阐明麻黄 - 五味子在哮喘管理中的活性成分和潜在机制。采用液相色谱串联质谱(LC-MS/MS)检测麻黄 - 五味子汤的主要成分。建立支气管哮喘大鼠模型,使用苏木精 - 伊红(HE)染色、免疫组织化学(IHC)染色、酶联免疫吸附测定(ELISA)、蛋白质印迹法(WB)和实时逆转录聚合酶链反应(RT-qPCR)研究麻黄 - 五味子的作用。
网络药理学预测结果显示,麻黄有22种活性成分,五味子有8种活性成分,共有225个潜在靶点。鉴定出1159个与哮喘相关的靶点以及115个药物与疾病之间重叠的靶点。这些靶点包括白细胞介素 - 6(IL-6)、肿瘤坏死因子(TNF)、肿瘤蛋白53、白细胞介素 - 1β(IL-1β)以及其他重要靶点。此外,哮喘与磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(AKT)信号通路、钙离子通道、核因子 - κB(NF-κB)信号通路以及其他信号通路之间存在潜在相关性。动物实验结果表明,与模型组相比,麻黄和五味子治疗可改善肺组织病理损伤,减少气道周围胶原纤维积聚和气道平滑肌增殖,降低肺组织中IL-6、TNF-α和IL-1β的浓度水平,并减轻气道炎症。此外,麻黄和五味子抑制卵清蛋白(OVA)致敏大鼠肺组织中磷脂酶C(PLC)、瞬时受体电位通道1(TRPC1)、肌球蛋白轻链激酶(MLCK)、NF-κB P蛋白的表达,并下调哮喘大鼠中PLC、TRPC1、PI3K、AKT、NF-κB P的mRNA表达。这些发现与网络药理学分析一致。
结果表明麻黄和五味子之间存在协同相互作用,它们可以通过抑制PLC/TRPC1/PI3K/AKT/NF-κB信号通路的表达有效减轻支气管哮喘大鼠吸入OVA诱导的气道重塑和气道炎症。因此,麻黄和五味子可能是治疗哮喘的潜在药物。